Cocrystal Pharma, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Cocrystal Pharma appointed Carol Brosgart, MD to its Board of Directors effective August 12, 2026. Dr. Brosgart is an accomplished antiviral specialist with decades of experience at Gilead Sciences (where she contributed to Viread and Hepsera approvals) and prior board seats at multiple biotech companies including Galmed, Eradivir, and Merlin. No compensation, equity, or financial terms are disclosed in this filing.
Why this rating
Board addition of experienced antiviral expert supports pipeline credibility at clinical-stage $11.6M company, but is routine governance change with no direct financial/operational impact disclosed.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.